סרוקואל 100 מג ישראל - עברית - Ministry of Health

סרוקואל 100 מג

tzamal pharma - quetiapine as fumarate - טבליות מצופות פילם - quetiapine as fumarate 100 mg - quetiapine - quetiapine - indicated for the treatment of schizophrenia. treatment of manic episodes associated with bipolar disorder. treatment of major depressive episodes in bipolar disorders.

לנלידומיד טבע  10 מג ישראל - עברית - Ministry of Health

לנלידומיד טבע 10 מג

teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 10 mg - lenalidomide

לנלידומיד טבע  15 מג ישראל - עברית - Ministry of Health

לנלידומיד טבע 15 מג

teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 15 mg - lenalidomide

לנלידומיד טבע  2.5 מג ישראל - עברית - Ministry of Health

לנלידומיד טבע 2.5 מג

teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 2.5 mg - lenalidomide

לנלידומיד טבע  20 מג ישראל - עברית - Ministry of Health

לנלידומיד טבע 20 מג

teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 20 mg - lenalidomide

לנלידומיד טבע  25 מג ישראל - עברית - Ministry of Health

לנלידומיד טבע 25 מג

teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 25 mg - lenalidomide

לנלידומיד טבע  5 מג ישראל - עברית - Ministry of Health

לנלידומיד טבע 5 מג

teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 5 mg - lenalidomide

לנלידומיד טבע  7.5 מג ישראל - עברית - Ministry of Health

לנלידומיד טבע 7.5 מג

teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 7.5 mg - lenalidomide

אפיניטור 5 מג ישראל - עברית - Ministry of Health

אפיניטור 5 מג

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אפיניטור 10 מג ישראל - עברית - Ministry of Health

אפיניטור 10 מג

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*